Arcturus Therapeutics Announces Third Quarter 2021 Financial Update and Pipeline Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St set to open higher as tech rebounds, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Stay long AI-capex winners into the peak, Stifel says despite bubble fears
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
UPDATE: Arcturus Therapeutics (ARCT) PT Raised to $30 at Goldman Sachs (CORRECTION)
November 9, 2021 6:51 AM EST(Updated - November 9, 2021 6:52 AM EST)
Goldman Sachs analyst Madhu Kumar raised the price target on Arcturus Therapeutics (NASDAQ: ARCT) to $30.00 (from $28.00) while maintaining a Sell rating.
... MoreArcturus Therapeutics (ARCT) Misses Q3 EPS by 46c
November 8, 2021 4:28 PM ESTArcturus Therapeutics (NASDAQ: ARCT) reported Q3 EPS of ($2.05), $0.46 worse than the analyst estimate of ($1.59).
For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.
... More